Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial.

Authors:
Address: Department of Infectious Diseases, Hamedan University of Medical Sciences, Hamedan, Iran.
Journal:

Publication:

abstract

BACKGROUND:

Traditional regimens for the treatment of brucellosis are associated with significant relapse rates. The aim of this study was to compare the efficacy of ofloxacin plus rifampin (OFX-RIF) versus doxycycline plus streptomycin (DOX-STR) and doxycycline plus rifampin (DOX-RIF) regimens in the treatment of brucellosis.

METHODS:

Two hundred and nineteen patients with brucellosis were enrolled in a randomized clinical trial; 28 cases were withdrawn because they did not attend the follow-up. Out of 191 patients with brucellosis, 64 received OFX-RIF, 62 received DOX-RIF, and 65 patients received DOX-STR regimens. All patients were assessed during the period of therapy in the second, fourth, and sixth weeks by clinical course and were also followed up clinically and serologically for 6 months after the cessation of therapy.

RESULTS:

The highest clinical response (95.4%) was observed in the DOX-STR group (p=0.009). The results of multivariate analysis indicate that treatment with DOX-STR had the least therapeutic failures among the three groups (p=0.033). Adverse reactions were seen in 16.8% of patients, but there was no significant difference among the three groups (p=0.613). The lowest relapse rate (4.6%) was observed in the DOX-STR group (p=0.109).

CONCLUSIONS:

We conclude that the DOX-STR combination should remain the first-line regimen for the treatment of brucellosis in our region; we recommend DOX-RIF and OFX-RIF combinations as the second-line regimens.

Related Articles
Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179].
BMC Infect Dis. 2004
Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179].
Karabay O, Sencan I, Kayas D, Sahin I. BMC Infect Dis. 2004 Jun 23; 4:18. Epub 2004 Jun 23.
Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.
Antimicrob Agents Chemother. 1...
Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.
Lang R, Shasha B, Rubinstein E. Antimicrob Agents Chemother. 1993 Nov; 37(11):2333-6.
Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis.
Int J Infect Dis. 2007
Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis.
Ranjbar M, Keramat F, Mamani M, Kia AR, Khalilian FO, Hashemi SH, Nojomi M. Int J Infect Dis. 2007 Mar; 11(2):152-6. Epub 2006 Jun 22.
Review Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials.
BMJ. 2008
Review Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials.
Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. BMJ. 2008 Mar 29; 336(7646):701-4. Epub 2008 Mar 5.
Review [Antibiotic treatment of brucellosis].
Presse Med. 1994
Review [Antibiotic treatment of brucellosis].
Bertrand A. Presse Med. 1994 Jun 25; 23(24):1128-31.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.